Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

American Journal of Clinical Dermatology - Tập 19 - Trang 457-457 - 2018
Andrew Blauvelt1, Kim A. Papp2, Christopher E. M. Griffiths3, Luis Puig4, Jamie Weisman5, Yves Dutronc6, Lisa Farmer Kerr6, Dapo Ilo6, Lotus Mallbris6, Matthias Augustin7
1Oregon Medical Research Center, Portland, USA
2K Papp Clinical Research and Probity Medical Research, Waterloo, Canada
3Dermatology Centre, Salford Royal Hospital, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
4Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
5Medical Dermatology Specialists, Inc., Atlanta, USA
6Eli Lilly and Company, Indianapolis, USA
7Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Tóm tắt

The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt

Thông tin
Thông tin xuất bản

American Journal of Clinical Dermatology

Tập 19

457-457

Thông tin tác giả